MedTrace Logo

Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients

NCT02363127 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-03-03

No results posted yet for this study

Summary

Randomised, prospective, investigator-blinded, controlled, single-centre study to assess the impact on the ongoing pregnancy rate with the use of two progesterones with different administration routes, in recipients of fresh embryos from donor oocytes, undergoing endometrial preparation for fresh embryo transfer.

Conditions

Interventions

DRUG

subcutaneous progesterone

subcutaneous progesterone 25 mg/day

DRUG

vaginal progesterone

vaginal progesterone in capsules 200 mg/3 times a day

Sponsors & Collaborators

  • Instituto Bernabeu

    lead OTHER

Principal Investigators

  • Joanquin Llacer, Ph · Instituto Bernabeu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363127 on ClinicalTrials.gov